> top > docs > PMC:7565482 > spans > 8462-9944 > annotations

PMC:7565482 / 8462-9944 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T37 230-233 Body_part denotes HIV http://purl.org/sig/ont/fma/fma278683
T38 453-464 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T39 563-566 Body_part denotes HLA http://purl.org/sig/ont/fma/fma84795
T40 894-905 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T41 1088-1097 Body_part denotes glutamine http://purl.org/sig/ont/fma/fma82752
T42 1163-1172 Body_part denotes glutamine http://purl.org/sig/ont/fma/fma82752
T43 1271-1282 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T1 920-929 Body_part denotes extension http://purl.obolibrary.org/obo/UBERON_2000106

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T35 831-839 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T66 17-24 http://purl.obolibrary.org/obo/PR_000018263 denotes Peptide
T67 98-106 http://purl.obolibrary.org/obo/PR_000018263 denotes peptides
T68 255-257 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T69 298-305 http://purl.obolibrary.org/obo/PR_000018263 denotes peptide
T70 868-869 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T71 891-893 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T72 1068-1070 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T73 1161-1162 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T74 1220-1227 http://purl.obolibrary.org/obo/PR_000018263 denotes peptide

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
101 831-841 Species denotes SARS-CoV-2 Tax:2697049
102 1088-1097 Chemical denotes glutamine MESH:D005973
103 1163-1172 Chemical denotes glutamine MESH:D005973

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T11 1220-1237 http://purl.obolibrary.org/obo/GO_0043043 denotes peptide synthesis
T12 1228-1237 http://purl.obolibrary.org/obo/GO_0009058 denotes synthesis

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T49 0-4 Sentence denotes 2.2.
T50 5-57 Sentence denotes Overlapping Peptide Set Design and Variability Plots
T51 58-259 Sentence denotes For the automated design of overlapping peptides with variable length, we used the previously described Peptgen algorithm available at the Los Alamos National Laboratories HIV Immunology database [48].
T52 260-367 Sentence denotes This OLP generator allows predefining peptide length and level of the desired overlap between adjacent OLP.
T53 368-599 Sentence denotes Peptgen is also set up to exclude from the C-terminal end of OLP certain “forbidden” amino acids (G, P, E, D, Q, N, T, S and C) that are rarely seen to serve as the C-terminal anchor position of HLA class I presented epitopes [49].
T54 600-796 Sentence denotes Using this optional modification can lead to length variation in the OLP set, which can be controlled by limiting the maximal length of an OLP in regions with numerous serial “forbidden” residues.
T55 797-1004 Sentence denotes The settings used for the present SARS-CoV-2 consensus OLP design were a) OLP length of 15 or 18 amino acids, with maximal extension or truncation of up to ±3 residues to avoid forbidden C-terminal residues.
T56 1005-1080 Sentence denotes In addition, the overlap between adjacent OLP was set at 10 or 11 residues.
T57 1081-1238 Sentence denotes The no-glutamine at N-terminal setting was applied to prevent OLP starting with a glutamine residue as this can lead to complications with peptide synthesis.
T58 1239-1401 Sentence denotes For positions where two or more amino acids were present above 25% of the sequences in the alignment, two or more sequence variants for those OLPs were generated.
T59 1402-1482 Sentence denotes Sequence logos were generated for these cases with the ggseqlogo R package [50].